Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 110

1.

Severe refractory asthma: current treatment options and ongoing research.

Menzella F, Bertolini F, Biava M, Galeone C, Scelfo C, Caminati M.

Drugs Context. 2018 Dec 5;7:212561. doi: 10.7573/dic.212561. eCollection 2018. Review.

2.

Dismissing the fallacies of childhood eczema management: case scenarios and an overview of best practices.

Hon KL, Leong KF, Leung TN, Leung AK.

Drugs Context. 2018 Dec 3;7:212547. doi: 10.7573/dic.212547. eCollection 2018. Review.

3.

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.

Kosmas CE, Silverio D, Sourlas A, Garcia F, Montan PD, Guzman E.

Drugs Context. 2018 Nov 28;7:212562. doi: 10.7573/dic.212562. eCollection 2018. Review.

4.

Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries.

Opris-Belinski D, Erdes SF, Grazio S, Šenolt L, Hojnik M, Nagy O, Marina D, Szántó S.

Drugs Context. 2018 Nov 21;7:212556. doi: 10.7573/dic.212556. eCollection 2018.

5.

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition.

Saad M, Gomceli U, Ravi P, Lacoste AG, Shah N, Vittorio TJ.

Drugs Context. 2018 Nov 21;7:212549. doi: 10.7573/dic.212549. eCollection 2018. Review.

6.

Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate.

Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL.

Drugs Context. 2018 Nov 14;7:212557. doi: 10.7573/dic.212557. eCollection 2018. Review.

7.

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors.

Fernandes MT, Adashek JJ, Barreto CMN, Spinosa ACB, de Souza Gutierres B, Lopes G, Del Giglio A, Aguiar PN Jr.

Drugs Context. 2018 Nov 5;7:212555. doi: 10.7573/dic.212555. eCollection 2018. Review.

8.

Sublingual allergen immunotherapy for respiratory allergy: a systematic review.

Blanco C, Bazire R, Argiz L, Hernández-Peña J.

Drugs Context. 2018 Nov 5;7:212552. doi: 10.7573/dic.212552. eCollection 2018.

9.

The biosimilars journey: current status and ongoing challenges.

Kos IA, Azevedo VF, Neto DE, Kowalski SC.

Drugs Context. 2018 Oct 1;7:212543. doi: 10.7573/dic.212543. eCollection 2018. Review.

10.

Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission.

Tull R, Hoover WD 3rd, De Luca JF, Huang WW, Jorizzo JL.

Drugs Context. 2018 Oct 2;7:212529. doi: 10.7573/dic.212529. eCollection 2018.

11.

Exploring the association of legalisation status of cannabis with problematic cannabis use and impulsivity in the USA.

Destrée L, Amiet D, Carter A, Lee R, Lorenzetti V, Segrave R, Youssef G, Solowij N, Yücel M.

Drugs Context. 2018 Sep 17;7:212541. doi: 10.7573/dic.212541. eCollection 2018.

12.

Primary genetic disorders affecting high density lipoprotein (HDL).

Kosmas CE, Silverio D, Sourlas A, Garcia F, Montan PD, Guzman E.

Drugs Context. 2018 Sep 11;7:212546. doi: 10.7573/dic.212546. eCollection 2018. Review.

13.

Spectral Doppler and automated software-guided ultrasound assessment of bilateral common carotid intima-media thickness in spondyloarthritis: is there a correlation with clinical findings?

Mendonça JA, de Andrade BB, de Aquino JLB, Leandro-Merhi VA, Damian GB.

Drugs Context. 2018 Sep 3;7:212538. doi: 10.7573/dic.212538. eCollection 2018.

14.

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.

Zhao Y, Singh RP.

Drugs Context. 2018 Aug 13;7:212532. doi: 10.7573/dic.212532. eCollection 2018. Review.

15.

Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review.

Ly S, Amici JM.

Drugs Context. 2018 Aug 20;7:212539. doi: 10.7573/dic.212539. eCollection 2018. Review.

16.

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment.

Anderson SL, Marrs JC.

Drugs Context. 2018 Aug 6;7:212542. doi: 10.7573/dic.212542. eCollection 2018. Review.

17.

Advances in the use of PARP inhibitor therapy for breast cancer.

McCann KE, Hurvitz SA.

Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018. Review.

18.

Febrile seizures: an overview.

Leung AK, Hon KL, Leung TN.

Drugs Context. 2018 Jul 16;7:212536. doi: 10.7573/dic.212536. eCollection 2018. Review.

19.

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors.

Cubero DIG, Abdalla BMZ, Schoueri J, Lopes FI, Turke KC, Guzman J, Del Giglio A, Filho CDSM, Salzano V, Fabra DG.

Drugs Context. 2018 Jul 17;7:212516. doi: 10.7573/dic.212516. eCollection 2018. Review.

20.

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Addeo A, Metro G.

Drugs Context. 2018 Jul 10;7:212537. doi: 10.7573/dic.212537. eCollection 2018.

Supplemental Content

Loading ...
Support Center